REFERENCES
- Strauss AJL, Seigal BC, Hsu KC. Immunofluorescence demonstration of a muscle binding complement fixing serum globulin fraction in myasthenia gravis. Proc Soc Exp Biol. 1960;105:184.
- Patric J, Lindstrom JM. Autoimmune response to acetylcholine receptor. Science. 1973;180:871.
- Benatar M, Kaminski HJ. Medical and surgical treatment for ocular myasthenia. Cochrane Database Syst Rev. Dec 2012;12:CD005081.
- Osserman KE. Ocular myasthenia gravis. Intest Ophthalmol. 1967;6:277–287.
- Castronuovo S, Krohel GB, Kristan RW. Blepharoptosis in myasthenia gravis. Ann Ophthalmol. 1983;15:751–4.
- Bradley EA, Bartley GB, Chapman KL, Waller RR. Surgical correction of blepharoptosis in patients with myasthenia gravis. Ophthal Plast Reconstr Surg. 2001;17:103–110.
- Litwan AS, Patel B, McNab AA, McCann JD, Leatherbarrow B, Malhotra R. Blephatoptosis surgery in patients with myasthenia gravis. Br J Ophthalmol. 2015;99:899–902.
- Kapetansky DI. Surgical correction of blepharoptosis in myasthenia gravis. Am J Ophthalmol. 1972;74:818–20.
- Carter SR, Meecham WJ, Seiff SR. Silicone frontalis slings for the correction of blepharoptosis: Indications and efficacy. Ophthalmology 1996;103:623–30.
- Shimizu Y, Suzuki S, Nagasao T, Ogato H, Yazawa M, Suzuki N, et al. Surgical treatment for medically refractory myasthenic blepharoptosis. Clin Ophthalmol. 2014; 8:1859–1867.
- Zach H, Cetin H, Hilger E, Paul A, Wuschitz B, Jung R, et al. The effect of early prednisolone treatment on the generalization rate in ocular myasthenia gravis. Eur J Neurol. 2013;20:708–13.
- Kupersmith MJ. Ocular myasthenia gravis: Treatment successes and failures in patients with long-term follow-up. J Neurol. 2009;256:1314–20.
- Schneider-Gold C, Gajdos P, Toyka KV, Hohlfeld RR. Corticosteroids for myasthenia gravis. Cochrane Database Syst. Rev. 2005;18:CD002828.;
- Sghirlanzoni A, Peluchetti D, Mantegazza R, Fiacchino F, Cornelio F. Myasthenia gravis: Prolonged treatment with steroids. Neurology 1984;32:170–174.
- Björnsson ES. Drug-induced liver injury: An overview over the most critical compounds. Arch Toxicol. 2015;89:327–34.
- Twork S, Wiesmeth S, Klewer J, Pöhlau D, Kugler J. Quality of life and life circumstances in German myasthenia gravis patients. Health Qual. Life Outcomes 2010;11:129.
- Burns TM, Grouse CK, Wolfe GI, Conaway MR, Sanders DB. The MG-QOL15 for following the health-related quality of life of patients with myasthenia gravis. Muscle Nerve 2011;43:14–8.
- Burns TM, Grouse CK, Conaway MR, Sanders DB. Construct and concurrent validation of the MG-QOL15 in the practice setting. Muscle Nerve 2010;41:219–26.
- Suzuki S, Murai H, Imai T, Nagane Y, Masuda M, Tsuda E, et al. Quality of life in purely ocular myasthenia in Japan. BMC Neurol. 2014;14:142.